Immunic (IMUX) Common Equity (2013 - 2026)

Immunic has disclosed Common Equity across 14 years of filings, most recently posting $151.2 million for Q1 2026.

• Common Equity for Q1 2026 came in at $151.2 million, up 2960.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $151.2 million (up 2960.47% YoY), and the FY2025 annual result was -$6.7 million, down 136.21% from the prior year.
• Common Equity came in at $151.2 million for Q1 2026 at Immunic, up from -$6.7 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $151.2 million in Q1 2026 to a low of -$6.7 million in Q4 2025.
• The 5-year median for Common Equity is $63.6 million (2024), against an average of $65.7 million.
• Across the five-year window, Common Equity slumped 136.21% in 2025 and soared 2960.47% in 2026, its largest moves.
• Immunic's Common Equity stood at $113.7 million in 2022, then tumbled by 74.55% to $28.9 million in 2023, then tumbled by 36.3% to $18.4 million in 2024, then plunged by 136.21% to -$6.7 million in 2025, then jumped by 2366.34% to $151.2 million in 2026.
• The last three Common Equity figures came in at $151.2 million (Q1 2026), -$6.7 million (Q4 2025), and $10.5 million (Q3 2025), per Business Quant data.